{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:17:08Z","timestamp":1791267428993,"version":"4.1.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0054769","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T22:03:54Z","timestamp":1359669834000},"page":"e54769","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":76,"title":["A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe\/PS1\u0394E9 Mouse Model of Alzheimer\u2019s Disease"],"prefix":"10.1371","volume":"8","author":[{"given":"Vadivel","family":"Parthsarathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"McClean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynn","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Kolosov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Masserini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allsop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset","volume":"88","author":"R Brookmeyer","year":"1998","journal-title":"Am J Public Health"},{"key":"ref2","unstructured":"American Health Assistance Foundation website. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ahaf.org\/alzheimers\/about\" xlink:type=\"simple\">http:\/\/www.ahaf.org\/alzheimers\/about<\/ext-link>. Accessed 2012 Nov 1."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 12, 383\u2013388.","DOI":"10.1016\/0165-6147(91)90609-V"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics","volume":"10","author":"E Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1523\/JNEUROSCI.1071-09.2009","article-title":"\u03b2-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin","volume":"29","author":"QL Ma","year":"2009","journal-title":"J Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b2 1\u201342 are potent central nervous system neurotoxins","volume":"95","author":"MP Lambert","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0006-8993(01)03058-X","article-title":"Soluble oligomers of \u03b2 amyloid (1\u201342) inhibit long-term potentiation but not long-term depression in rat dentate gyrus","volume":"924","author":"HW Wang","year":"2002","journal-title":"Brain Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"DM Walsh","year":"2002","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1096\/fj.01-0987fje","article-title":"Selective neuronal degeneration induced by soluble oligomeric amyloid \u03b2 protein","volume":"17","author":"HJ Kim","year":"2003","journal-title":"FASEB J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-\u03b2 protein specifically disrupt cognitive function","volume":"8","author":"JP Cleary","year":"2005","journal-title":"Nature Neurosci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A\u03b2 oligomers - a decade of discovery","volume":"101","author":"DM Walsh","year":"2007","journal-title":"J Neurochem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide","volume":"8","author":"C Haass","year":"2007","journal-title":"Nature Rev Mol Cell Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer\u2019s disease: strategies for disease modification","volume":"9","author":"M Citron","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1096\/fj.04-1764com","article-title":"Targeting the neurotoxic species in Alzheimer\u2019s disease: inhibitors of A\u03b2 oligomerization","volume":"18","author":"FG De Felice","year":"2004","journal-title":"FASEB J"},{"key":"ref15","first-page":"1611","article-title":"APP transgenic mice and their application to drug discovery","volume":"26","author":"D Howlett","year":"2011","journal-title":"Histol Histopathol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/bi100144m","article-title":"Development of a proteolytically stable retro-inverso peptide inhibitor of \u03b2-amyloid oligomerization as a potential novel treatment for Alzheimer\u2019s disease","volume":"20","author":"M Taylor","year":"2010","journal-title":"Biochemistry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.271.15.8545","article-title":"Arrest of \u03b2-amyloid fibril formation by a pentapeptide ligand","volume":"271","author":"LO Tjernberg","year":"1996","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"12619","DOI":"10.1074\/jbc.274.18.12619","article-title":"A molecular model of Alzheimer amyloid \u03b2-peptide fibril formation","volume":"274","author":"LO Tjernberg","year":"1999","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0076-6879(06)13015-3","article-title":"Peptide-based inhibitors of amyloid assembly","volume":"413","author":"KL Sciarretta","year":"2006","journal-title":"Methods Enzymol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1006\/bbrc.1996.1413","article-title":"Inhibition of Alzheimer\u2019s amyloidosis by peptides that prevent \u03b2-sheet conformation","volume":"226","author":"C Soto","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0798-822","article-title":"\u03b2-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer\u2019s therapy","volume":"4","author":"C Soto","year":"1998","journal-title":"Nature Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"8237","DOI":"10.1021\/bi002416v","article-title":"Inhibition of \u03b2-amyloid (40) fibrillogenesis and disassembly of \u03b2-amyloid (40) fibrils by short \u03b2-amyloid congeners containing N-methyl amino acids at alternate residues","volume":"40","author":"DJ Gordon","year":"2001","journal-title":"Biochemistry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"9906","DOI":"10.1021\/bi060837s","article-title":"N-Methylated peptide inhibitors of \u03b2-amyloid aggregation and toxicity. Optimization of the inhibitor structure","volume":"45","author":"N Kokkoni","year":"2006","journal-title":"Biochemistry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"29525","DOI":"10.1074\/jbc.271.47.29525","article-title":"A strategy for designing inhibitors of \u03b2-amyloid toxicity","volume":"271","author":"J Ghanta","year":"1996","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.0.CO;2-E","article-title":"\u03b2-sheet breaker peptide inhibitor of Alzheimer\u2019s amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma","volume":"39","author":"JF Poduslo","year":"1999","journal-title":"J Neurobiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1021\/bi982824n","article-title":"Modified-peptide inhibitors of amyloid \u03b2-peptide polymerization","volume":"38","author":"MA Findeis","year":"1999","journal-title":"Biochemistry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"M Green","year":"1988","journal-title":"Cell"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF03033773","article-title":"Surface plasmon resonance for the analysis of \u03b2-amyloid interactions and fibril formation in Alzheimer\u2019s disease research","volume":"7","author":"MI Aguilar","year":"2005","journal-title":"Neurotox Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"013705","DOI":"10.1063\/1.2432410","article-title":"WSXM: a software for scanning probe microscopy and a tool for nanotechnology","volume":"78","author":"I Horcas","year":"2007","journal-title":"Rev Sci Instrum"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Imai Y, Kohsaka S (2002) Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia 40, 164\u2013174.","DOI":"10.1002\/glia.10149"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1006\/bbrc.1996.1112","article-title":"A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage","volume":"224","author":"Y Imai","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0896-6273(00)80778-3","article-title":"Doublecortin is a microtubule associated protein and is expressed widely by migrating neurons","volume":"23","author":"JG Gleeson","year":"1999","journal-title":"Neuron"},{"key":"ref33","first-page":"836","article-title":"Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide","volume":"6","author":"S Ramanathan","year":"2009","journal-title":"Mol Phar"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.mcn.2004.03.005","article-title":"Delivery of bioactive molecules into the cell: the Trojan horse approach","volume":"27","author":"GP Dietz","year":"2004","journal-title":"Mol Cell Neurosci"},{"key":"ref35","first-page":"40","article-title":"Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso Tat cell penetrating peptide","volume":"150","author":"X Zhang","year":"2007","journal-title":"Neuroscience"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1023\/A:1010932126662","article-title":"Time-course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation","volume":"18","author":"M Repici","year":"2001","journal-title":"Pharm Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1021\/bc025526i","article-title":"Multiple-peptide conjugates for binding \u03b2-amyloid plaques of Alzheimer\u2019s disease","volume":"14","author":"G Zhang","year":"2003","journal-title":"Bioconj Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"29390","DOI":"10.1074\/jbc.272.46.29390","article-title":"Slow degradation of aggregates of the Alzheimer\u2019s disease amyloid \u03b2-protein by microglial cells","volume":"114","author":"D Paresce","year":"1997","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"P McClean","year":"2011","journal-title":"J Neurosci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/cbic.200700338","article-title":"Branched KLVFF tetramers strongly potentiate inhibition of \u03b2-amyloid aggregation","volume":"8","author":"SM Chafekar","year":"2007","journal-title":"ChemBioChem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nano.2011.06.015","article-title":"Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer\u2019s A\u03b2 peptide","volume":"7","author":"M Taylor","year":"2011","journal-title":"Nanomedicine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/nbdi.1998.0193","article-title":"Possible causes of Alzheimer\u2019s disease: amyloid fragments, free radicals, and calcium homeostasis","volume":"5","author":"C H\u00f6lscher","year":"1998","journal-title":"Neurobiol Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"35789","DOI":"10.1074\/jbc.C500238200","article-title":"Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer\u2019s disease and familial British dementia","volume":"280","author":"BJ Tabner","year":"2005","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/978-1-4419-6327-7_13","article-title":"Amyloid peptide pores and the \u03b2 sheet conformation","volume":"677","author":"BL Kagan","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/NEN.0b013e318248e614","article-title":"The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons","volume":"71","author":"A Nunomura","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11481-011-9312-5","article-title":"Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?","volume":"7","author":"C Cunningham","year":"2011","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1126\/science.1088417","article-title":"Inflammatory blockade restores adult hippocampal neurogenesis","volume":"302","author":"ML Monje","year":"2003","journal-title":"Science"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: clinical trials and drug development","volume":"9","author":"F Mangialasche","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1515\/bc.2010.089","article-title":"Is BACE1 a suitable therapeutic target for the treatment of Alzheimer\u2019s disease? Current strategies and future directions","volume":"391","author":"DW Klaver","year":"2010","journal-title":"Biol Chem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nurt.2008.05.010","article-title":"Inhibition and modulation of \u03b3-secretase for Alzheimer\u2019s disease","volume":"5","author":"MS Wolfe","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nrn938","article-title":"Amyloid-\u03b2 immunotherapy for Alzheimer\u2019s disease: the end of the beginning","volume":"3","author":"D Schenk","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"F Yang","year":"2005","journal-title":"J Biol Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1016\/j.bmc.2011.07.033","article-title":"Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"19","author":"SY Chen","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"PE Cramer","year":"2012","journal-title":"Science"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e11101","DOI":"10.1371\/journal.pone.0011101","article-title":"Complete phenotypic recovery of an Alzheimer\u2019s disease model by a quinone-tryptophan hybrid aggregation inhibitor","volume":"5","author":"R Scherzer-Attali","year":"2010","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3233\/JAD-2010-091195","article-title":"Administration of amyloid-\u03b242 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice","volume":"23","author":"Y Zhang","year":"2011","journal-title":"J Alzheimers Dis"}],"updated-by":[{"DOI":"10.1371\/annotation\/57e0a947-8600-4658-b04c-cf7a45c8bd8d","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T00:00:00Z","timestamp":1379635200000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0054769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:50:39Z","timestamp":1588999839000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0054769"}},"subtitle":[],"editor":[{"given":"Damian Christopher","family":"Crowther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0054769","relation":{"correction":[{"id-type":"doi","id":"10.1371\/annotation\/57e0a947-8600-4658-b04c-cf7a45c8bd8d","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}